Sorafenib Treatment in Advanced Hepatocellular Carcinoma with Tumor Thrombus Nearly Occupying the Entire Right Atrium

Kang, Young Mo; Ryu, Soo Hyung; Lee, Bo Kyung; Ko, Kyoung Ho; Park, Tae Young; Moon, Jeong Seop; Cho, Seon Hwa

doi:10.17998/jlc.18.2.142

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to research estimates, there were 18.1 million new cancer cases and 9.6 million cancer deaths worldwide in 2018 [ 2 , 3 ]. Among them, hepatocellular carcinoma (HCC) ranks seventh among all types of cancer [ 4 ]. In China, HCC is one of the most widespread malignancies and one of the leading causes of cancer death, accounting for more than 50% of new cases and deaths worldwide [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A

Lin

Zhang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has high morbidity and mortality. MicroRNAs (miRNAs), which could be regulated by cancer-derived exosomes, play critical regulatory roles in the initiation and development of cancer. However, the expressions, effects, and mechanisms of abundant miRNAs regulated by HCC cancer-derived exosomes in HCC remain largely unclear. Exosomes of HepG2 cells under heat shock, TGF-β1, doxorubicin, acid and hypoxia/reoxygenation (H/R) conditions, and exosomes were successfully identified by transmission electron microscopy and Western blot analysis. The identified exosomes were then applied to evaluate the miRNA expression profiles by RNA sequencing. Mechanically, we discovered that doxorubicin was upregulated, TGF-β1 downregulated the expressions of Vps4A, Rab27A, Alix, and Hrs in HepG2 cells and exosomes, and Vps4A and Rab27A, as target genes for miR-4454, could also be downregulated by miR-4454. Functionally, we revealed that miR-4454 inhibitor and miR-4454 inhibitor-mediated exosomes could markedly suppress proliferation, migration, invasion, and vascularization and accelerate cycle arrest, apoptosis, and ROS of HepG2 cells. This study provided many potential HCC cancer-derived exosome-mediated miRNAs in HCC under 5 different stimulus conditions. Meanwhile, we certified that miR-4454 in exosomes could provide a novel and effective mechanism for HCC function.

show abstract

Section: Introductionmentioning

confidence: 99%

miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A

Lin

Zhang

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

Hepatocellular Carcinoma with Hepatic Vein and Inferior Vena Cava Invasion

Shukla¹,

Shukla²

2023

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Clinical outcome and toxicity of radiotherapy for inferior vena cava tumor thrombus in HCC patients

2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) involving the inferior vena cava rarely occurs, but its prognosis is extremely poor, with no established treatment to date. This study aimed to analyze the clinical outcome and toxicity of radiotherapy (RT) targeting inferior vena cava tumor thrombus (IVCTT) in HCC patients. From November 2011 to July 2020, medical record of 19 HCC patients who were treated with RT for IVCTT was retrospectively reviewed. RT was delivered using 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, and stereotactic body radiation therapy. The median radiation dose was 50 Gy (range, 45–55.8 Gy) for intensity-modulated radiation therapy and three-dimensional conformal radiotherapy. Stereotactic body radiation therapy was performed in 5 patients, for a total of 32 Gy in 4 fractions. The median follow-up duration was 8.1 months (range, 3.3–26.5 months). The median overall survival was 9.4 months (range, 3.7–26.5 months), and the 1-year overall survival rate was 37.1%. Eight of 19 patients (42.1%) had extrahepatic metastasis at the start of RT. Six of 11 patients (54.5%) who did not have extrahepatic metastasis at the start of RT showed extrahepatic metastasis after RT. The major cause of death was progression of extrahepatic metastasis (11 patients, 57.9%). The overall response rate of IVCTT for RT was 84.2%, and the local control rate at the time of the last follow-up was 89.4%. After RT, the most common first progression site was the lungs (9 patients, 47.4%). Most toxicities were grade 1 to 2 gastrointestinal (26.3%) and liver enzyme elevation (68.4%). Three patients occurred pulmonary embolism after RT later than 5 months after. RT is a feasible and safe local therapy for IVCTT, with favorable tumor control and acceptable toxicity. Extrahepatic metastasis is the major progression pattern and a leading cause of death in patients treated with RT. The combination of effective systemic therapy with RT may have to be considered.

show abstract

Sorafenib Treatment in Advanced Hepatocellular Carcinoma with Tumor Thrombus Nearly Occupying the Entire Right Atrium

Cited by 3 publications

References 5 publications

miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A

miR-4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A

Hepatocellular Carcinoma with Hepatic Vein and Inferior Vena Cava Invasion

Clinical outcome and toxicity of radiotherapy for inferior vena cava tumor thrombus in HCC patients

Contact Info

Product

Resources

About